DAHANCA 5
DAHANCA 5 is the trial that made hypoxic sensitisation real in the clinic: nimorazole with radiotherapy improved control of head and neck cancer, and Denmark has used it as standard ever since.
Overview
DAHANCA 5 randomised 422 patients with carcinoma of the supraglottic larynx or pharynx to nimorazole or placebo during conventional radiotherapy. Five-year locoregional control was 49 percent with nimorazole and 33 percent with placebo, with a survival advantage in the pharynx subgroup and minimal added toxicity (Overgaard and colleagues, Radiotherapy and Oncology 1998). A later analysis showed the benefit was confined to tumours with a hypoxic gene signature, and a European confirmatory trial (EORTC 1219) followed.
- 49 vs 33 out of 100 reached this endpoint at 5 years with Nimorazole plus radiotherapy compared with Placebo plus radiotherapy; 16 more per 100.
- Roughly one extra person helped for every 6 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- This endpoint is not one of the standard survival or response measures; read it alongside the trial's primary result.
- These results apply to the people the trial enrolled: Supraglottic larynx and pharynx cancer treated with radiotherapy: the hypoxic radiosensitiser nimorazole versus placebo. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
422 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Locoregional control at 5 yearsprimary | Nimorazole plus radiotherapy | 219 | 49% | - | - | - |
| Placebo plus radiotherapy | 203 | 33% |
Similar pages
not linked directly; found by shared links- TrialRTOG 0617
Shares Radiosensitisers and the tag radiation-wave2.
- TechnologyDose painting and biologically guided radiotherapy
Shares Tumour hypoxia, Head and neck squamous cell carcinoma.
- TechnologyHyperthermia
Shares Tumour hypoxia, Tumour hypoxia: imaging and modification, Radiosensitisers.
- CompanyNanobiotix
Shares Radiosensitisers, Head and neck squamous cell carcinoma.
- TrialBonner trial (cetuximab plus radiotherapy)
Shares Radiosensitisers, Head and neck squamous cell carcinoma.
- TreatmentNBTXR3 (hafnium oxide nanoparticles)
Shares Radiosensitisers, Head and neck squamous cell carcinoma.
- TrialRTOG 91-11
Shares Radiosensitisers, Head and neck squamous cell carcinoma.